PDPN and neoplasm: In cancer, the interaction of CLEC‐2 with podoplanin‐expressing tumour cells promotes angiogenesis, tumour growth and metastasis, and may represent a target for therapy, if the side‐effects on the haemostatic functions of the receptor can be overcome 11.